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Abstract
Background: The preoperative C-reactive protein/Albumin (CRP/Alb) ratio has been shown to be valuable in predicting
the prognosis of patients with certain cancers. The aim of our study is to explore its prognostic value in patients with
renal cell carcinoma (RCC).
Methods: A retrospective study was performed in 570 RCC patients underwent radical or partial nephrectomy including
541 patients who received full resection of localized (T1-3 N0/+ M0) RCC. The optimal cutoff value of CRP/Alb was
determined by the receive operating characteristic (ROC) analysis. The impact of the CRP/Alb and other clinicopathological
characteristics on overall survival (OS) and disease-free survival (DFS) was evaluated using the univariate and multivariate
Cox regression analysis.
Results: The optimal cutoff of CRP/Alb ratio was set at 0.08 according to the ROC analysis. Multivariate analysis indicated
that CRP/Alb ratio was independently associated with OS of RCC patients underwent radical or partial nephrectomy
(hazard ratio [HR]: 1.94; 95% confidence interval [95% CI]: 1.12–3.36; P = 0.018), and DFS of localized RCC patients
underwent full resection (HR: 2.14; 95% CI: 1.22–3.75; P = 0.008).
Conclusion: Elevated CRP/Alb ratio was an independent prognostic indicator for poor OS in patients underwent
radical or partial nephrectomy and DFS of localized RCC patients underwent full resection. Overall, CRP/Alb may help
to identify patients with high relapse risk.
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Background
Renal cell carcinoma (RCC) is the most common malig-
nancy in females with urological tumors and ranks the
third place in males after prostate and bladder cancers
[1]. Broad applications of radiological technologies espe-
cially abdominal ultrasound or computerized tomog-
raphy have led to increase in detection of renal tumors
in relatively small size and localized in the kidney [2].
Patients with localized diseases usually undergo curative
whole or partial nephrectomy. However, up to 40% pa-
tients will eventually relapse with secondary tumors at
distant sites [3, 4]. At first presentation, one-third of all
RCC patients will have established metastatic renal cell
carcinoma (mRCC). Despite the introduction of molecu-
lar targeted therapies, the overall 5-year survival rate of
this patient group rarely exceeds 10% [5, 6]. In addition,
RCC is characterized by chemo- and radio-resistance.
The clinical course in localized RCC is difficult to pre-
dict, even within patients who have similar clinic-
pathological parameters, such as tumor stage and grade
[7, 8]. Therefore, it is important to identify promising
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prognostic factors to guide patient management after
curative surgery treatment.
Increasing evidences have demonstrated the role of in-
flammation in carcinogenesis and tumor progression.
The prognostic value of many inflammation-based
scores, such as preoperative C-reactive protein (CRP),
the Glasgow Prognostic Score (GPS), modified Glasgow
prognostic score (mGPS), high-sensitivity modified
Glasgow prognostic score (HS-mGPS), neutrophil to
lymphocyte ratio (NLR), platelet to lymphocyte ratio
(PLR), and systemic immune-inflammation index (SII),
has been validated in many types of cancer, including
RCC [9–13]. Additionally, some studies have demon-
strated that the preoperative nutritional status, such as
hypoalbuminemia, weight loss and low body mass index
(BMI), are associated with worse outcomes of RCC
patients after radical or partial nephrectomy [14, 15].
Recently, a new prognostic index, preoperative C-
reactive protein/albumin (CRP/Alb) ratio, in combin-
ation with the systemic inflammation and nutritional
status, has also been reported as an independent prog-
nostic marker in hepatocellular cancer (HCC), gastric
cancer (GC) and small-cell lung cancer (SCLC) [16–18].
Although Chen et al. reported the prognostic influence
of CRP/Alb ratio on overall survival (OS) of patients
Table 1 Baseline characteristics of all patients (n = 570)
Characteristics Cases (n = 570) Percentage (%)
Age (years) (Mean ± SD) 51.43 ± 13.52





Clear cell carcinoma 451 79.10
















































< 1.85 242 42.50
≥ 1.85 328 57.50
PLR
< 153 418 73.30
≥ 153 152 26.70
CRP/Alb
< 0.08 393 68.90
≥ 0.08 177 31.10
Abbreviation: BMI body mass index, pTNM pathologic tumor–node–metastasis,
ALP alkaline phosphatase, LDH lactate dehydrogenase, CRE serum creatinine,
UA uric acid, LDH lactate dehydrogenase, NLR neutrophil count to lymphocyte
count, PLR platelet count to lymphocyte count, CRP/Alb the serum CRP level to
the serum Alb level
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with clear cell renal carcinoma [19], its prognostic role
in RCC still need to be further explored. In this retro-
spective study, we examined the prognostic value of
CRP/Alb ratio in patients with RCC and investigated the
relationship between CRP/Alb ratio and the clinical out-
comes of RCC patients.
Methods
Patients
We executed a retrospective cohort study of 912
consecutive RCC patients who underwent radical or
partial nephrectomy between January 2000 and
December 2012 in Sun Yat-sen University Cancer
Center (SYSUCC). The inclusion criteria were as fol-
lows: 1) patients were cytologically or histologically
diagnosed with RCC; 2) data on complete blood la-
boratory measurements included serum CRP and al-
bumin (Alb) within one week before performing
radical or partial nephrectomy. Patients without blood
laboratory measurements prior to surgical resection,
patients with active inflammatory disease and patients
with other malignancies were excluded from the
study. At last, a total of 570 patients were enrolled in
the study. This retrospective study was conducted in
accordance with the standards of the Declaration of
Helsinki and was approved by the Sun Yat-sen
University Cancer Center research ethics committee
(Number: GZR2016-100). All patients have provided
written informed consent for their information to be
stored and used in the hospital database.
Clinical data extraction
The baseline clinical and pathologic characteristics were
collected, including age at the time of surgery, gender,
BMI, lactate dehydrogenase (LDH), urine protein, alka-
line phosphatase (ALP), serum creatinine (CRE), uric
acid (UA), total protein, serum globulin, neutrophil
count, lymphocyte count, platelet count, disease stage
and histology by using a standard data extraction system.
Elevated ALP level was defined as serum ALP > 135 U/L.
Elevated LDH was defined as serum LDH > 245 U/L. El-
evated CRE was defined as serum CRE > 130 μmol/L. El-
evated UA was defined as UA > 420 μmol/L. Elevated
total protein was as total protein > 80 g/L. Elevated
globulin was defined as globulin > 35 g/L. Tumor stage
was determined based on the 2010 TNM classification
of malignant tumors staging system and tumor grade
was defined according to the Fuhrman grading system.
All the blood samples were tested prior to initial treat-
ment. The NLR, PLR and CRP/Alb ratio were calculated
based on the following equations, respectively.
NLR ¼ neutrophil count to lymphocyte count;
PLR ¼ platelet count to lymphocyte count;
CRP=Alb ¼ the serum CRP level to the serum Alb level:
Patients follow-up
A dynamic computed tomogram was performed every
3 months in two years, 6 months in 2–5 years and 1 year
after 5 years. The last survival follow-up date was
Fig. 1 The predictive ability of the preoperative NLR, PLR and CRP/Alb ratio was compared by ROC curves
Guo et al. BMC Cancer  (2017) 17:171 Page 3 of 13
November 01, 2015. Overall survival (OS) was calculated
from the date of surgery to the date of death or last
follow-up. Disease-free survival (DFS) was calculated
from the date of surgery to the date of disease recur-
rence or metastasis or the last follow-up in localized
RCC patients who underwent full resection.
Statistical analysis
Descriptive statistics of patients’ characteristics (i.e. age
and BMI) were presented as mean ± SD (standard devi-
ation). Comparisons between groups were performed
using the Kruskal-Wallis or χ2 test. Pearson correlation
was performed to evaluate the relationship of serum
CRP and Alb with OS. The optimal cut-off points for
the inflammation-based factors were determined by re-
ceive operating characteristic (ROC) analysis and the
areas under the curve (AUC) were calculated. Survival
analysis and curves were performed according to the
Kaplan-Meier method and compared by the log-rank
test. A Cox proportional-hazard model for multivariable
analysis was applied for variables that proved to be
significant in the univariate analysis. Hazard ratios
(HR) with 95% confidence interval (95% CI) were also
calculated using univariate or multivariate analysis. If
variables were significantly associated with other
Table 2 Clinicopathological variables of patients according to
the cutoff value of CRP/Alb ratio





Age (years) 48.71 ± 12.98 55.25 ± 13.92 <0.001a
BMI 23.65 ± 3.37 23.41 ± 4.02 0.290a
Gender 0.219b
Male 257 (65.40%) 125 (70.60%)
Female 136 (34.60%) 52 (29.40%)
Pathological types 0.315b
Clear cell carcinoma 308 (81.20%) 43 (80.80%)
Papillary carcinoma 26 (3.80%) 15 (8.50%)
Others 59 (15.00%) 19 (10.70%)
Fuhrman-grade <0.001b









IV 5 (1.30%) 24(13.60%)
pT status <0.001b
T1 318 (80.90%) 89 (50.30%)
T2 54 (13.70%) 40 (22.60%)
T3+ T4 21 (5.30%) 48 (27.10%)
pN status <0.001b
N0 382 (97.20%) 153 (86.40%)
N1 11 (2.80%) 24 (13.60%)
pM status <0.001b
M0 390 (99.20%) 160 (90.40%)
M1 3 (0.80%) 17 (9.60%)
Urine protein 0.188b
No 319 (81.20%) 141 (79.7%)
Yes 15 (3.80%) 13 (7.3%)
Unknown 59 (15.00%) 23 (13.00%)
ALP 0.018b
Normal 369 (93.90%) 156 (88.10%)
Elevated 24 (6.10%) 21 (11.90%)
LDH 0.004b
Normal 335 (85.20%) 133 (75.10%)
Elevated 58 (14.80%) 44 (24.90%)
CRE 0.001b
Normal 384 (97.70%) 162 (91.50%)
Table 2 Clinicopathological variables of patients according to
the cutoff value of CRP/Alb ratio (Continued)
Elevated 9 (2.30%) 15 (8.50%)
UA 0.468b
Normal 321 (81.70%) 140 (79.10%)
Elevated 72 (18.30%) 37 (20.90%)
Total protein 0.144b
Normal 352 (89.60%) 151 (85.30%)
Elevated 41 (10.40%) 26 (14.70%)
Serum globulin
Normal 273 (69.50%) 87 (49.20%) <0.001b
Elevated 120 (30.50%) 90 (50.80%)
NLR <0.001b
< 1.85 205 (52.20%) 37 (20.90%)
≥ 1.85 188 (47.80%) 140 (79.10%)
PLR <0.001b
< 153 324 (82.40%) 94 (53.10%)
≥ 153 69 (17.60%) 83 (46.90%)
Abbreviation: BMI body mass index, pTNM pathologic tumor–node–metastasis,
ALP alkaline phosphatase, LDH lactate dehydrogenase, CRE serum creatinine,
UA uric acid, LDH lactate dehydrogenase, NLR neutrophil count to lymphocyte
count, PLR platelet count to lymphocyte count, CRP/Alb the serum CRP level to
the serum Alb level
aKruskal-Wallis test
bChi-square test
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variables, they were excluded from the final multivari-
able analysis. Statistical analyses were performed using
IBM SPSS 21.0 software (IBM Corporation, Armonk,
NY). Differences at p < 0.05 were considered to be
significant in all statistical analyses.
Results
Patient demographics and outcomes
The clinicpathological characteristics of the 570 RCC pa-
tients were summarized in Table 1. Their mean age was
51.43 ± 13.52 years old and their mean and median
follow-up periods were 65.19 and 63.54 months, respect-
ively. Among them, 382 (67%) were males and 188 (33%)
were females; 81 (14.2%) died and 489 (85.8%) survived
at last follow-up. There were 451 (79.10%) patients with
clear cell, 41 (7.20%) with papillary, 78 (13.70%) with
others RCC (such as 27 (4.70%) with chromophobe, 10
(1.80%) with multilocular cystic, 41 (7.20%) with other
histological types of RCC). The overall cancer-specific
survival (CSS) was 93.1% at 1 year, 89.6% at 2 years, and
81.6% at 5 years.
The relationship of serum CRP and Alb with OS
We explored the association of the serum CRP and Alb
with OS. The results showed a significant negative cor-
relation between serum CRP level and OS (r = −0.141, P
< 0.001) (Additional file 1: Figure S1a) and a significant
positive correlation between serum Alb level and OS
(r =0.317, P < 0.001) (Additional file 1: Figure S1b).
The optimal cut-off value of inflammation-based factors
by the ROC analysis
Based on the area under ROC curve (AUC) of 0.715 (P
< 0.001) for survival in the ROC analysis, the optimal
cut-off value was 0.08 for CRP/Alb ratio. 1.85 for NLR
and 153 for PLR, respectively. The sensitivity and
specificity of CRP/Alb ratio were 66.7 and 75.1%, re-
spectively. In addition, the ability to distinguish CRP/Alb
ratio from other inflammation-based prognostic factors
was compared using the levels of AUC. The results
showed that was 0.675 and 0.704 for NLR and PLR, re-
spectively (Fig. 1 and Additional file 2: Table S1). Based
on the cut-off value of CRP/Alb ratio, 177(31.1%) pa-
tients were assigned into low CRP/Alb group and 393
(68.9%) patients were in the high CRP/Alb group.
The clinicopathological characteristics and the
preoperative CRP/Alb ratio
The clinicopathological characteristics of all patients are
described in Table 2. An elevated CRP/Alb ratio was sig-
nificantly associated with the Fuhrman-grade (P < 0.001),
T stage (P < 0.001), N stage (P < 0.001), M stage (P <
0.001), ALP (P = 0.018), LDH (P = 0.004), NLR (P <
0.001) and PLR (P < 0.001). For patients in the low CRP/
Alb ratio group, 94.7% were at stag T1/T2 and 5.3% at
stage T3/T4. However, for patients in the high CRP/Alb
ratio group, only 72.9% patients were at stage T1/T2 and
27.1% at T3/T4 (P < 0.001). Similarly, the percentage of
patients at stage N0/N1 was 97.2%/2.8% and that of pa-
tients at stage M0/M1 was 99.2%/0.8% in patients in the
low CRP/Alb ratio group. By comparison, the percentage
of patients at N0/N1 was 86.4%/13.6% and at stage M0/
M1 was 90.4%/9.6% in the high CRP/Alb ratio group (P
< 0.001). These results indicate that CRP/Alb ratio is as-
sociated with the disease progression and low CRP/Alb
ratio is related with the early stage of RCC.
The relationship between the preoperative CRP/Alb ratio
and OS in all RCC patients
Compared with high CRP/Alb ratio, patients with low
CRP/Alb ratio had longer OS (CRP/Alb 0.08 vs. ≥0.08,
mean OS: 164.87 vs 79.92 months, P 0.001) (Fig. 2b).
Fig. 2 Kaplan-Meier curves depicting DFS (n = 541) and OS (n = 570) according to the preoperative optimal value of CRP/Alb in patients with renal cell
carcinoma. a Kaplan-Meier analysis of DFS in 541 patients. b Kaplan-Meier analysis of OS in 570 patients
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Fig. 3 (See legend on next page.)
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Similarly, longer OS was also observed in patients in the
low CRP/Alb group at early stage T1/T2 (P 0.001), at
the advanced stage T3/T4 (P = 0.003), at N0 (P 0.001),
N1(P = 0.006), M0 (P 0.001) stages, but not at M1stage
(P = 0.869) (Fig. 3).
Table 3 shows the results of the univariate and multi-
variate analysis of OS. It is clear from the univariate ana-
lysis that the CRP/Alb ratio is associated with the OS of
RCC patients (HR: 5.55; 95% CI: 3.48–8.86; P < 0.001).
After excluding the related variables, the significant vari-
ables (age, BMI, T stage, N stage, M stage, NLR, PLR
and CRP/Alb ratio) were tested in the multivariate ana-
lysis. The multivariate analysis indicated that the CRP/
Alb ratio (HR: 1.94; 95% CI: 1.12–3.36; P =0. 018) is an
independent prognostic factor for OS in addition to N
stage (HR: 3.62; 95% CI: 1.91–6.85; P < 0.001), M stage
(HR: 3.12; 95% CI: 1.57–6.19; P = 0.001) and PLR
(HR: 2.42; 95% CI: 1.43–4.07; P < 0.001), but not LDH
and NLR.
The relationship between the preoperative CRP/Alb ratio
and DFS in localized (T1-3 N0/+ M0) RCC patients
underwent full resection
The clinicopathological characteristics of 541 localized
(T1-3 N0/+ M0) RCC patients underwent full resection
were summarized in Additional file 3: Table S2. CRP/
Alb ratio was used to analyze the DFS of these patients,
who were considered as received the curative treatment.
Among them, patients with low CRP/Alb ratio had lon-
ger DFS event than patients in the high CRP/Alb ratio
group (CRP/Alb 0.08 vs. ≥0.08, mean DFS: 166.75 vs
85.58 months, P 0.001) (Fig. 2a). In addition, DFS of
patients at stages T1, T2, T3,N0 and N1 in the low CRP/
Alb ratio group also had longer DFS event than patients
in the high CRP/Alb ratio group (P < 0.001, P = 0.032, P
= 0.044, P < 0.001 and P = 0.004, respectively) (Fig. 4).
Table 4 showed the results of univariate and multivari-
ate analyses of DFS. It is clear from the univariate ana-
lysis results that CRP/Alb ratio is associated with DFS of
localized RCC patients underwent full resection (HR:
4.22; 95% CI: 2.54–7.02; P <0.001). The multivariate ana-
lysis also indicated that CRP/Alb ratio (HR: 2.14; 95%
CI: 1.22–3.75; P = 0.008) is an independent prognostic
factor for DFS of these patients. In addition, age (HR:
1.03; 95% CI: 1.01–1.06; P <0.001), BMI (HR: 0.89; 95%
CI: 0.82–0.97; P = 0.005), N stage (HR: 4.70; 95% CI:
2.19–10.09; P <0.001) and PLR (HR: 2.44; 95% CI: 1.38–
4.32; P =0 .002) are also independent prognostic factors
for DFS of RCC patients.
Discussion
In this study, we retrospectively analyzed the prog-
nostic value of CRP/Alb ratio in 570 RCC patients
received radical or partial nephrectomy in our institu-
tion. Among them, 541 patients with localized (T1-
3 N0/+ M0) RCC and subjected to full resection were
also analyzed. The results demonstrated that CRP/Alb
ratio is an independent prognostic factor for patients
with RCC.
Although the basal CRP level is affected by genetic
and environmental factors [20, 21], CRP is produced
mainly by hepatocytes and is regulated by pro-
inflammatory cytokines, especially interleukin-6 [22].
Increased CRP level has been reported in many types
of cancers [23–25]. The potential mechanisms for
the association of CRP with cancer have been pro-
posed. (1) Tissue inflammation was caused by the
tumor growth may result in increased CRP levels
[26]. (2) The elevated CRP could be an indicative
biomarker of immune responses to tumor antigens
[27]. (3) Tumor cells could produce more inflamma-
tory proteins including CRP [24] or enhanced
interleukin-6 and interlukin-8 in tumor cells could
indirectly increase CRP expression [28]. Jabs WJ et
al. showed that activity of the IL-6/CRP network in
RCC patients contributes to the acute-phase reaction
in local inflammatory processes [29]. Other clinical
data also showed that elevated CRP level is associ-
ated with poorer OS of RCC patients [30, 31] and
CRP has a significant impact on OS of metastatic
RCC patients treated with a tyrosine kinase inhibitor,
either sunitinib or sorafenib [32, 33].
Hypoalbuminemia is not a perfect indicator of nutri-
tional status because of its long half-life and the poten-
tial influence of system factors such as inflammation and
stress on serum Alb. However, it is an easy, reproducible
assessment and closely correlated with other markers of
nutritional status [34]. In addition, serum Alb as a
biomarker of protein-energy malnutrition can provide
essential information that supplementary to BMI and
changes in body weight, which may not accurately re-
flect the nutritional status due to normal limits [35].
(See figure on previous page.)
Fig. 3 Kaplan-Meier curves showing OS according to the preoperative optimal value of CRP/Alb in 570 patients with renal cell carcinoma. Patients
were stratified according to the pT-status, pN-status, and pM-status. a Kaplan-Meier analysis of OS in T1-2 subgroup. b Kaplan-Meier analysis of OS in
T3-4 subgroup. c Kaplan-Meier analysis of OS in N0 subgroup. d Kaplan-Meier analysis of OS in N1 subgroup. e Kaplan-Meier analysis of OS inM0
subgroup. f Kaplan-Meier analysis of OS in M1 subgroup
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Table 3 Univariate and multivariate analyses for variables considered for overall survival (OS) (Cox proportional hazard regression
model) (n = 570)
OS Univariate analysis OS Multivariate analysis
Characteristics 95% CIs HR P value 95% CIs HR P value
Age (years) 1.01 to 1.05 1.03 <0.001a 1.01 to 1.05 1.03 <0.001b
BMI 0.82 to 0.93 0.87 <0.001a 0.84 to 0.97 0.91 0.007b
Gender
Male 1.00(ref.)
Female 0.73 to 1.82 1.16 0.532a
Pathological types
Clear cell carcinoma 1.00(ref.) 1.00(ref.)
Papillary carcinoma 1.36 to 4.72 2.53 0.003a 0.67 to 4.39 1.72 0.258b
Others 0.70 to 2.42 1.30 0.414a 0.64 to 3.99 1.60 0.312b
Fuhrman-grade
I 1.00(ref.) 1.00(ref.)
II 0.68 to 2.82 1.39 0.365a 0.72 to 3.21 1.52 0.269b
III 1.46 to 7.14 3.23 0.004a 0.57 to 3.09 1.33 0.507b
IV 1.70 to 22.12 6.14 0.006a 0.43 to 6.08 1.62 0.474b
unknown 1.25 to 5.19 2.55 0.010a 0.43 to 2.55 1.05 0.922b
pTNM stage
I 1.00(ref.)
II 1.27 to 4.85 2.48 0.008a
III 3.51 to 11.40 6.33 <0.001a
IV 14.54 to 46.54 26.01 <0.001a
pT status
T1 1.00(ref.) 1.00(ref.)
T2 1.76 to 5.46 3.10 <0.001a 1.20 to 3.90 2.16 0.011b
T3+ T4 4.72 to 12.92 7.81 <0.001a 0.91 to 3.13 1.69 0.098b
pN status
N0 1.00(ref.) 1.00(ref.)
N1 6.42 to 17.09 10.47 <0.001a 1.91 to 6.85 3.62 <0.001b
pM status
M0 1.00(ref.) 1.00(ref.)
M1 8.71 to 26.12 15.08 <0.001a 1.57 to 6.19 3.12 0.001b
Urine protein
No 1.00(ref.)
Yes 0.46 to 2.84 1.14 0.773a
Unknown 0.48 to 1.74 0.92 0.787a
ALP
Normal 1.00(ref.)
Elevated 0.61 to 2.63 1.27 0.527a
LDH
Normal 1.00(ref.)
Elevated 0.84 to 2.34 1.40 0.203a
CRE
Normal 1.00(ref.)
Elevated 0.78 to 4.07 1.78 0.175a
UA
Normal 1.00(ref.)
Elevated 0.77 to 4.08 1.78 0.176a
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Table 3 Univariate and multivariate analyses for variables considered for overall survival (OS) (Cox proportional hazard regression
model) (n = 570) (Continued)
Total protein
Normal 1.00(ref.)
Elevated 0.77 to 2.54 1.40 0.265a
Serum globulin
Normal 1.00(ref.) 1.00(ref.)
Elevated 1.66 to 4.03 2.59 <0.001a 0.84 to2.31 1.39 0.203b
NLR
< 1.85 1.00(ref.) 1.00(ref.)
≥ 1.85 3.08 to 11.59 5.97 <0.001a 0.97 to 4.32 2.05 0.060b
PLR
< 153 1.00(ref.) 1.00(ref.)
≥ 153 3.49 to 8.56 5.46 <0.001a 1.43 to 4.07 2.42 <0.001b
CRP/Alb
< 0.08 1.00(ref.) 1.00(ref.)
≥ 0.08 3.48 to 8.86 5.55 <0.001a 1.12 to 3.36 1.94 0.018b
Abbreviation: HR hazard ratio, CIs confidence intervals, BMI body mass index, pTNM pathologic tumor–node–metastasis, ALP alkaline phosphatase, LDH lactate
dehydrogenase, CRE, serum creatinine, UA, uric acid, LDH lactate dehydrogenase, NLR neutrophil count to lymphocyte count, PLR platelet count to lymphocyte
count, CRP/Alb the serum CRP level to the serum Alb level
aUnivariate Cox proportional hazard regression
bMultivariate Cox proportional hazard regression
Fig. 4 Kaplan-Meier curves showing DFS according to the preoperative optimal value of CRP/Alb in 541 patients with renal cell carcinoma. Patients
were stratified according to the pT-status, pN-status. a Kaplan-Meier analysis of DFS in T1 subgroup. b Kaplan-Meier analysis of DFS in T2 subgroup.
c Kaplan-Meier analysis of DFS in T3 subgroup. d Kaplan-Meier analysis of DFS in N0 subgroup. e Kaplan-Meier analysis of DFS in N1 subgroup
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Table 4 Univariate and multivariate analyses for variables considered for disease-free survival (DFS) (Cox proportional hazard regression
model) (n = 541)
DFS Univariate analysis DFS Multivariate analysis
Characteristics 95% CIs HR P value 95% CIs HR P value
Age (years) 1.02 to 1.05 1.03 0.002a 1.01 to 1.06 1.03 <0.001b
BMI 0.79 to 0.93 0.86 <0.001a 0.82 to 0.97 0.89 0.005b
Gender
Male 1.00(ref.)
Female 0.57 to 1.66 0.97 0.921a
Pathological types
Clear cell carcinoma 1.00(ref.) 1.00(ref.)
Papillary carcinoma 1.15 to 4.80 2.35 0.019a 0.62 to 2.99 1.47 0.431b
Others 0.33 to 1.80 0.77 0.550a 0.32 to 1.91 0.78 0.587b
Fuhrman-grade
I 1.00(ref.)
II 0.62 to 2.68 1.28 0.504a
III 1.01 to 5.86 2.44 0.047a
IV 0.97 to 20.24 4.99 0.055a
unknown 0.68 to 3.40 1.53 0.299a
pTNM stage
I 1.00(ref.)
II 1.33 to 4.84 2.54 0.005a
III 3.54 to 11.08 6.26 <0.001a
pT status
T1 1.00(ref.) 1.00(ref.)
T2 1.57 to 5.03 2.81 <0.001a 1.29 to 4.35 2.38 0.005b
T3 2.20 to 8.03 4.20 <0.001a 0.65 to 2.72 1.33 0.437b
pN status
N0 1.00(ref.) 1.00(ref.)
N1 3.72 to 13.73 7.15 <0.001a 2.19 to 10.09 4.70 <0.001b
Urine protein
No 1.00(ref.)
Yes 0.44 to 3.40 1.23 0.691a
Unknown 0.28 to 1.49 0.64 0.301a
ALP
Normal 1.00(ref.)
Elevated 0.19 to 2.02 0.63 0.440a
LDH
Normal 1.00(ref.)
Elevated 0.84 to 2.69 1.51 0.168a
CRE
Normal 1.00(ref.)
Elevated 0.59 to 4.51 1.64 0.341a
UA
Normal 1.00(ref.)
Elevated 0.44 to 1.69 0.86 0.654a
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Protein malnutrition can lead to edema, impaired
organ function and immunosuppression. Moreover,
preoperative hypoalbuminemia is associated with
higher mortality in patients with underwent surgery
for RCC [14, 36, 37].
Recently, CRP/Alb ratio has been used to predict the
prognosis of several cancers [16–18]. In this study, we
used the ROC analysis to yield a 0.08 cutoff value for
CRP/Alb ratio for predicting OS in RCC. Compared
with the other systemic inflammatory markers NLR and
PLR, CRP/Alb ratio has the highest AUC value (P <
0.001). Univariate analyses showed that higher CRP/Alb
ratio is associated with poorer prognosis (P < 0.001).
Patients with CRP/Alb ratio ≥ 0.08 had a 5.5-higher mor-
tality risk than patients with CRP/Alb ratio < 0.08. Multi-
variate analyses also showed that CRP/Alb ratio is
independently predictable factor for OS of patients with
RCC (P = 0.018). Furthermore, RCC patients at stage T1/
T2, stage T3/T4, N0, N1 and M0, but M1, in the low
CRP/Alb group had significantly longer OS than their
counterparts in the high CRP/Alb group (P < 0.001, P <
0.001, P < 0.001, P = 0.006 and P < 0.001, respectively).
Therefore, low CRP/Alb ratio is associated with the early
stage RCC disease and high CRP/Alb ratio present the
advanced or metastatic RCC suggesting that CRP/Alb
ratio could be a new prognostic indicator related to the
progression of RCC. More importantly, CRP/Alb ratio is
also a predictor for recurrence or metastasis of localized
(T1-3 N0/+ M0) RCC patients underwent full resection.
In general, T1/T2 is staged as localized disease in RCC.
However, patients at T1-3N1M0 stages underwent full
resection may be also considered to receive a curative
therapy. So far, although target reagent clinical trials for
localized (T1-3N1M0) RCC patients using adjuvant ther-
apy including axitinib are ongoing, there is no standard
therapy for those patients after surgery. Therefore, look-
ing for predict markers for full resection in localized
(T1-3/N1 M0) RCC patients can avoid excessive treat-
ment and help clinicians to identify high-risk patients
for closer follow-up. Multivariate analysis of these 541
patients after adjustment for other variables including
cancer stage, CRP/Alb ratio was an independent prog-
nostic factor for DFS of patients in full resection of
localized RCC (P = 0.008). Patients underwent full resec-
tion of localized RCC in the low CRP/Alb group showed
significantly longer DFS than patients underwent full re-
section of localized RCC in the high CRP/Alb group (P
< 0.001). Further analyses also suggested that patients
underwent full resection at T1, T2, T3, N0 and N1
stages in the low CRP/Alb group had longer DFS than
their counterparts in the high CRP/Alb group. To our
best knowledge, this is the first report showing that
CRP/Alb ratio can predict the DFS of localized RCC
underwent full resection. These results are crucial for
clinicians to make a decision for full resection of local-
ized RCC and important to increase the accuracy of the
established prognostic factors. The study also demon-
strates that CRP/Alb ratio may serve as a screening
Table 4 Univariate and multivariate analyses for variables considered for disease-free survival (DFS) (Cox proportional hazard regression
model) (n = 541) (Continued)
Total protein
Normal 1.00(ref.)
Elevated 0.37 to 1.97 0.85 0.704a
Serum globulin
Normal 1.00(ref.) 1.00(ref.)
Elevated 1.26 to 3.40 2.07 0.004a 0.69 to 2.05 1.19 0.533b
NLR
< 1.85 1.00(ref.) 1.00(ref.)
≥ 1.85 2.06 to 7.58 3.95 <0.001a 0.78 to 3.37 1.62 0.193b
PLR
< 153 1.00(ref.) 1.00(ref.)
≥ 153 2.54 to 6.92 4.19 <0.001a 1.38 to 4.32 2.44 0.002b
CRP/Alb
< 0.08 1.00(ref.) 1.00(ref.)
≥ 0.08 2.54 to 7.02 4.22 <0.001a 1.22 to 3.75 2.14 0.008b
Abbreviation: HR hazard ratio, CIs confidence intervals, BMI body mass index, pTNM pathologic tumor–node–metastasis, ALP alkaline phosphatase, LDH lactate
dehydrogenase, CRE serum creatinine, UA uric acid, LDH lactate dehydrogenase , NLR neutrophil count to lymphocyte count, PLR platelet count to lymphocyte count,
CRP/Alb the serum CRP level to the serum Alb level
aUnivariate Cox proportional hazard regression
bMultivariate Cox proportional hazard regression
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method to choose the appropriate follow-up strategy for
patients with localized RCC underwent full resection.
Our findings have some clinical implications. Firstly,
compared with the preoperative NLR and PLR, the pre-
operative CRP/Alb ratio is more effective and suitable
prognostic indicator in patients with RCC. Secondly, ac-
cording to the preoperative CRP/Alb ratio, patients with
high risk can be selected for further management and
treatment. Thirdly, our result can be used to stratify pa-
tients who are more likely to respond to biomarker-
based enrichment strategy in future clinical trials. Our
study also has several limitations. First, it is a retrospect-
ive and single-center study, which may limit the
prognostic value of the CRP/Alb ratio. Therefore, a
large-scale prospective validation study is needed. Sec-
ond, several other factors that are influential to in-
flammation such as life styles and smoking status
were not included in the study. Third, DFS was re-
corded based on radio-examination which may be
longer than the actual DFS as some patients admitted
to hospital only when they had obvious symptoms. In
summary, this study demonstrated that CRP/Alb ratio
is an independent predictor of OS for patients with
RCC and can be used to predict the relapse or metastasis
of localized RCC patients underwent full resection.
Conclusion
Overall, we demonstrate that preoperative CRP/Alb ratio
is an independent prognostic marker for OS of RCC pa-
tients after radical or partial nephrectomy. In addition,
preoperative CRP/Alb ratio could be used to predict
DSF of localized RCC patients who underwent curative
treatment and help clinicians to identify the high-risk
patients for closer follow-up.
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